ATC Group: C09DB05 Irbesartan and amlodipine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C09DB05 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C09 Agents acting on the renin-angiotensin system
3 C09D Angiotensin II antagonists, combinations
4 C09DB Angiotensin II antagonists and calcium channel blockers
5 C09DB05 Irbesartan and amlodipine

Active ingredients in C09DB05

Active Ingredient

The pharmacodynamic properties of each drug, irbesartan and amlodipine, provide an additive antihypertensive effect when administered in combination compared to the effect of each drug administered separately. Irbesartan is a specific angiotensin II receptor antagonist (AT1 subtype) and amlodipine is a dihydropyridine calcium antagonist. Both AT1 receptor antagonists and calcium channel blockers lower blood pressure by reducing peripheral resistance, but calcium influx blockade and reduction of angiotensin II vasoconstriction are complementary mechanisms.

Related product monographs

Document Type Information Source  
 APROVASC Film-coated tablet MPI, Generic Marketing Authorisation Holder

Medicines classified under this ATC code globally

Ecuador (EC)

Japan (JP)

Mexico (MX)

Nigeria (NG)

Romania (RO)

South Africa (ZA)

Tunisia (TN)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.